Welcome to our dedicated page for Pacira BioSciences news (Ticker: $PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira BioSciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pacira BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pacira BioSciences's position in the market.
Pacira BioSciences, Inc. announced a proposed offering of $250.0 million aggregate principal amount of convertible senior notes due 2029. The company intends to use the net proceeds for various purposes, including repurchasing existing notes, funding capped call transactions, and repurchasing shares of common stock. The offering is aimed at qualified institutional buyers and will involve privately negotiated capped call transactions to reduce potential dilution to common stock. Overall, the offering is part of Pacira's strategic financial planning to support its corporate goals.
Pacira BioSciences, Inc. (Nasdaq: PCRX) reported strong financial results for Q1 2024, with total revenues of $167.1 million. Net product sales included $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera°. The company also announced a $150 million share repurchase program, presented positive efficacy and safety data for PCRX-201, granted RMAT designation to PCRX-201, and secured three new EXPAREL patents. Financially, GAAP net income was $9.0 million, non-GAAP net income was $31.1 million, and adjusted EBITDA was $44.6 million. Pacira reaffirmed its 2024 financial guidance with a strong outlook for the year.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will be held in New York, with live audio accessible on the company's website. A replay will be available for two weeks.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will release its first quarter financial results on May 7, 2024, followed by a live conference call and webcast. Participants can dial 1-800-715-9871 (passcode 6363041) or 1-646-307-1963 for international callers. The webcast will be available on the Pacira website.